Stay updated on Anamorelin HCl in NSCLC-Cachexia Clinical Trial
Sign up to get notified when there's something new on the Anamorelin HCl in NSCLC-Cachexia Clinical Trial page.

Latest updates to the Anamorelin HCl in NSCLC-Cachexia Clinical Trial page
- CheckyesterdayChange DetectedA site-wide NIH notice announces a transition in terminology from “Artificial Intelligence” to “Super Intelligence” and links to updates and FAQs.SummaryDifference1%

- Check7 days agoChange DetectedThe footer revision identifier changes from v3.7.1 to v3.7.2 on the ClinicalTrials.gov 403 error page.SummaryDifference0.2%

- Check14 days agoChange DetectedThe site footer now displays revision v3.7.1 instead of v3.7.0, while the study record page continues to show a 403 Forbidden error.SummaryDifference0.2%

- Check35 days agoChange DetectedThe page now displays a 403 Forbidden error page, replacing the previous detailed study record content; navigation and site chrome remain, while the study content is not accessible on this page.SummaryDifference16%

- Check42 days agoChange DetectedThe study locations now list Tel Litwinsky, Israel and no longer include Qiryat Krinitzi, Israel, updating the geographic sites for ROMANA 2 recruitment.SummaryDifference0.1%

- Check49 days agoChange DetectedThe study location list was updated to include Qiryat Krinitzi, Israel and remove Tel Litwinsky, Israel, reflecting changes to participating centers.SummaryDifference0.1%

Stay in the know with updates to Anamorelin HCl in NSCLC-Cachexia Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Anamorelin HCl in NSCLC-Cachexia Clinical Trial page.